Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2146970
Max Phase: Preclinical
Molecular Formula: C68H104N14O10
Molecular Weight: 1277.67
Molecule Type: Small molecule
Associated Items:
ID: ALA2146970
Max Phase: Preclinical
Molecular Formula: C68H104N14O10
Molecular Weight: 1277.67
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(C)(C)C[C@@H]1NC(=O)[C@H](CCCN)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCCN)NC(=O)[C@H](CC23CC4CC(CC(C4)C2)C3)NC(=O)[C@H](CCCN)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCCN)NC1=O
Standard InChI: InChI=1S/C68H104N14O10/c1-67(2,3)40-53-61(87)73-47(20-10-26-69)57(83)77-51(35-42-16-6-4-7-17-42)65(91)82-31-15-25-56(82)64(90)76-50(23-13-29-72)60(86)80-54(41-68-37-44-32-45(38-68)34-46(33-44)39-68)62(88)74-48(21-11-27-70)58(84)78-52(36-43-18-8-5-9-19-43)66(92)81-30-14-24-55(81)63(89)75-49(22-12-28-71)59(85)79-53/h4-9,16-19,44-56H,10-15,20-41,69-72H2,1-3H3,(H,73,87)(H,74,88)(H,75,89)(H,76,90)(H,77,83)(H,78,84)(H,79,85)(H,80,86)/t44?,45?,46?,47-,48-,49-,50-,51+,52+,53-,54-,55-,56-,68?/m0/s1
Standard InChI Key: YJYVWQABHRWNST-VLZCIJPCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1277.67 | Molecular Weight (Monoisotopic): 1276.8060 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Kapoerchan VV, Knijnenburg AD, Keizer P, Spalburg E, de Neeling AJ, Mars-Groenendijk RH, Noort D, Otero JM, Llamas-Saiz AL, van Raaij MJ, van der Marel GA, Overkleeft HS, Overhand M.. (2012) 'Inverted' analogs of the antibiotic gramicidin S with an improved biological profile., 20 (20): [PMID:22989907] [10.1016/j.bmc.2012.08.038] |
Source(1):